Evogene (Israel) Today
| EVGN Stock | ILA 599.80 0.20 0.03% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Evogene is trading at 599.80 as of the 27th of November 2024, a 0.03 percent decrease since the beginning of the trading day. The stock's open price was 600.0. Evogene has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Evogene are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of October 2024 and ending today, the 27th of November 2024. Click here to learn more.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel. EVOGENE operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. The company has 41.22 M outstanding shares. More on Evogene
Moving together with Evogene Stock
Moving against Evogene Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Evogene Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Evogene's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Evogene or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Ofer Haviv |
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Evogene (EVGN) is traded on Tel Aviv Stock Exchange in Israel and employs 133 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 121.59 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Evogene's market, we take the total number of its shares issued and multiply it by Evogene's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Evogene operates under Biotechnology sector and is part of Health Care industry. The entity has 41.22 M outstanding shares.
Evogene has accumulated about 65.36 M in cash with (24.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.61.
Check Evogene Probability Of Bankruptcy
Ownership AllocationEvogene holds a total of 41.22 Million outstanding shares. Evogene shows 3.58 percent of its outstanding shares held by insiders and 3.37 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Evogene Ownership Details
Evogene Risk Profiles
Although Evogene's alpha and beta are two of the key measurements used to evaluate Evogene's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.3 | |||
| Standard Deviation | 4.85 | |||
| Variance | 23.48 | |||
| Risk Adjusted Performance | (0.29) |
Evogene Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Evogene without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run CEOs Directory Now
CEOs DirectoryScreen CEOs from public companies around the world |
| All Next | Launch Module |
Evogene Corporate Directors
| Oded Shoseyov | Director | Profile | |
| Adina Makover | Independent Director | Profile | |
| Adrian Percy | Director | Profile | |
| Sarit Firon | Independent Director | Profile |
Additional Information and Resources on Investing in Evogene Stock
When determining whether Evogene offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evogene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evogene Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evogene Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Evogene Stock refer to our How to Trade Evogene Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.